Papertrade, a high-leverage trading platform, decided to keep its PAPER tokens locked within platform contracts after receiving about $140 million in user deposits. This move prevents users from transferring PAPER tokens off-platform, a shift from initial plans that listed token transfers as a later phase. The platform's concern is that allowing free transfers could enable profitable price manipulation attacks involving Bitcoin and Ether. Critics argue this limits trader flexibility, but Papertrade emphasizes the risk and responsibility were disclosed in advance. Despite restrictions, PAPER staking rewards continue, reflecting genuine user engagement rather than token farming.
Papertrade's PAPER token transfer plan is the story subject, with Pluang market data providing context. As of Oct 24, 2026 20:01 WIB, 5 of 50 major cryptocurrencies rose while 43 fell. Notable movers include DOT at Rp19.268 down 10.36%, BAT at Rp2.878 down 9.83%, and EOS at Rp12.649 up 8.13%.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
